What Will Be the Impact of Adding High Alcohol Oral Formulations to Schedule H1?

The Ministry of Health and Family Welfare has released a new rule called the Drugs (Tenth Amendment) Rules, 2026. According to this regulation, all those liquid drugs that are highly alcoholic in nature have been put in Schedule H1. After doing this, the said drugs cannot be purchased without a prescription from a physician, and pharmacists will maintain a record of each sale made.

What Are High-Alcohol Oral Formulations Under the New Rule?

The 2026 amendment describes a clear group of medicines that now fall under stricter rules. A medicine belongs to this group if it meets all three conditions below:

• It is taken by mouth (an oral formulation).
• It contains more than 12% alcohol by volume (ethyl alcohol).
• It is sold in a bottle or pack larger than 30 millilitres.
• Common examples of such products include:
• Cough syrups with a high amount of alcohol.
• Liquid tonics that use alcohol to dissolve their ingredients.
• Large bottles of liquid medicine with a noticeable alcohol content.

From now on, these products are treated the same way as other controlled prescription medicines listed under Schedule H1.

What Has Changed in the Drugs Rules, 1945?

The two important changes to the Drugs Rules, 1945 are:

1. Change to Schedule K (Exemptions)

Schedule K is a list of medicines and situations that are excused from following the full Drugs Act and Rules. Serial number 10 of this list, under the heading "Extent and Conditions of Exemptions," has been edited.

After the words "Act and rules thereunder," new wording has been added:

"Except for all oral formulations containing more than 12% alcohol v/v (Ethyl Alcohol) packed and sold in packings or bottles of more than 30 milliliters."

What this means: High-alcohol liquid medicines sold in bottles larger than 30 ml no longer get the exemption under Schedule K serial 10. Full compliance with the Act and Rules becomes compulsory.

2. Addition to Schedule H1 (Controlled Medicines List)

Schedule H1 is the list of medicines that need extra care because of their risk of misuse. A new line has been added right after entry "51. Pregabalin":

"52. All oral formulations containing more than 12% alcohol v/v (Ethyl Alcohol) are packed and sold in packings or bottles of more than 30 milliliters."

What this means: These medicines now count as Schedule H1 items, which brings three main results:

• Sale is allowed only with a valid prescription.
• Pharmacies must maintain extra records of each sale.
• Sale over the counter, without a prescription, is no longer permitted.

Implementation Date and Compliance Timeline

Firstly, in this rule itself, there is a mention that:

• These rules can be termed the Drugs (Tenth Amendment) Rules, 2026.
• These will come into force six months from the date of their publication in the official gazette.

Since the publication date is 10 July 2026, the rule is set to take effect around 10 January 2027. This gives businesses roughly six months to complete several tasks:

• Identify which products are affected.
• Update product labels and packaging details.
• Revise sales and distribution procedures.
• Train staff on how to handle Schedule H1 products correctly.

Why Did the Ministry of Health and Family Welfare Introduce This Rule?

The notification provides an overview of the steps taken before finalising the rule:

• The draft of the rule was published on 16 October 2025.
• The public had 30 days to object or suggest any changes.
• Drafts of the rule were published on 18 October 2025, but no objections or suggestions were received from the public.
• The Central Government adopted the rule after consulting with the Drugs Technical Advisory Board (DTAB).

The main reasons behind this decision include:

1. Preventing Misuse

High-alcohol liquid medicines can sometimes be misused as a substitute for alcoholic drinks. Placing them under Schedule H1 ensures a doctor stays involved and misuse is kept in check.

2. Protecting Public Health

Large bottles with 12% or more alcohol content may cause intoxication or even damage to health when consumed inappropriately.

3. Removing Confusion

Taking these products out of the Schedule K exemption list and clearly adding them to Schedule H1 removes any doubt about how they should be classified.

4. Matching Existing Safety Rules

Schedule H1 also regulates medicinal drugs that have an abuse potential. Introducing high-alcohol formulations will only make it easy for these products to align with an existing regulation for this purpose.

Generally, the intention is to regulate dangerous products and not promote the consumption of alcohol.

Impact on Businesses in India

Affected Stakeholders

•    Manufacturer of oral liquid medicines containing more than 12% ethanol.
•    Contract manufacturer of high-alcohol formulations.
•    Distributors and wholesalers handle these liquid medicines.
•    Retail and hospital pharmacies that stock such products.

Compliance Requirements

For Manufacturers

Review the full product list to find: 

• Oral formulations containing more than 12% ethanol.
• Pack sizes larger than 30 ml.
• Reclassify the affected products as Schedule H1, which includes: 
• Updating labels and pack declarations.
• Adjusting marketing and distribution practices.
• Consider available options, such as: 
• Lowering the alcohol content to 12% or below.
• Reducing the pack size to 30 ml or less.
• Discontinuing products where the cost of compliance outweighs the business return.

For Distributors and Wholesalers

• Keep a clear list of all Schedule H1 products handled.
• Supply these products only to properly licensed pharmacies.
• Update documentation practices to track high-alcohol Schedule H1 items.

For Retail Pharmacies

• Consider all these products as Schedule H1 medicines.
• Sell these products on prescription only.
• Maintain proper registers and records regarding Schedule H1 products.

Is This Rule a Right Decision or an Extra Burden?

From a Public Health and Regulatory Perspective

This step appears reasonable and necessary for a few reasons:

• High-alcohol formulations carry a real risk of misuse.
• Moving them into Schedule H1 places them under closer medical supervision.
• The rule was finalised only after consultation with DTAB, and the public raised no objections.
• It does not create unfairness for pharma companies or consumers:
• Consumers are not being pushed toward more alcohol access is being managed more carefully.
• Businesses that adapt responsibly can strengthen their reputation for trustworthiness.

Business Burden

There is, admittedly, some extra work involved:

• More record-keeping is required.
• Sales may dip for products that were previously easier to buy.
• Some products may need reformulation or a change in pack size.

That said, this burden is:

• Reasonable when measured against the risk involved.
• Manageable with proper planning.
• An opportunity for companies to show leadership in following regulations.

Consumer Safety, Quality, and Long-Term Satisfaction

Quality and Safety

The Schedule H1 will offer many advantages, such as:

• Greater supervision of the quality of manufacture and distribution.
• Improved monitoring of adverse effects and misuse patterns.
• Assurance that high-risk medicines are handled properly within the medical system.

Consumer Satisfaction

In the short term:

• Some inconvenience may arise due to the prescription requirement.

In the long term:

• Safety outcomes are likely to improve.
• Harm linked to misuse is likely to decrease.
• Confidence grows that medicines are used correctly rather than as a substitute for alcohol.

Impact on the Indian Economy and International Players

Indian Economy

The overall effect on the economy is modest but positive:

• A slight shift is expected in how controlled formulations are sold.
• Manufacturers are encouraged to reformulate and create safer products.
• Reduced misuse is likely to ease pressure on the healthcare system over time.

Foreign and Multinational Pharma

International companies will need to adjust their Indian product lines by:

• Reformulating products where needed.
• Adjusting pack sizes.
• Updating labelling and compliance processes.

Clear rules like this one make the Indian market more predictable and reduce regulatory uncertainty for foreign players.

Opportunities for Related Businesses

Pharma Manufacturers

Reformulation and Innovation 

• Development of low-alcohol or alcohol-free alternatives.
• Introduction of smaller pack sizes where clinically suitable.

Portfolio Rationalisation 

• Phasing out high-risk products that are no longer commercially viable.
• Greater focus on safer, compliant products.

Distributors and Pharmacies

• Building strong systems to manage controlled drugs.
• Using digital registers and standard procedures for Schedule H1 compliance.
• Turning compliance into a way of earning trust with hospitals and doctors.

Health-Tech and Software Providers

Designing pharmacy software that:

• Flags Schedule H1 products automatically.
• Requires prescription details before a sale is completed.
• Maintains the statutory logs and reports required by law.

Corpseed's Business Opportunities Under the New Rule

Corpseed is well placed to help businesses adjust to and benefit from this new classification:

1. Product Portfolio Compliance Audit

Reviewing client product lists to identify formulations with more than 12% ethanol in packs larger than 30 ml.

Providing a clear mapping of products against the new regulatory requirements.

2. Reformulation and Pack-Size Advisory

In support of the decision-making process related to lowering alcohol levels, altering packaging size, and withdrawing specific products depending on risk and reward.

3. Labelling and Documentation Compliance

Ensuring correct Schedule H1 markings, updated labels and packaging artwork, and full alignment with the Drugs Rules, 1945.

4. Pharmacy and Distribution Compliance Programs

Provision of accurate Schedule H1 labelling and packaging artwork in full compliance with the Drugs Rules, 1945.

5. Training Modules for Sales and Pharmacy Staff

Creating simple training material covering topics such as "What is Schedule H1?" and "How to handle high-alcohol formulations safely."

6. International Client Support

Advice to multinational pharma companies regarding new Indian regulations on product modification and other issues related to compliance and the regulatory process.

7. Ongoing Regulatory Monitoring Service

Tracking future changes to Schedules K and H1 and alerting clients early to any new controlled categories.

By positioning itself as a specialist in pharma and healthcare compliance, Corpseed can turn this rule into a long-term line of advisory and implementation work.